HomeNewsNeuroscienceMigraine

  • FDA approves Galcanezumab (Emgality) for Preventive Migraine Treatment

    • October 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Teva Announces AJOVY™ (fremanezumab) approval in the US market

    • September 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Increased Anxiety & Depression in Higher frequency Migraine patients, new research study says

    • August 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novartis wins Aimovig approval for launch in the EU markets

    • August 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Unprecedented demand for Aimovig reflects strong unmet need in Migraine, says Novartis CEO

    • July 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • ICER report gives thumbs up to Aimovig for Chronic Migraine patients

    • July 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New Ph 3 Efficacy data presented for Eptinezumab in Episodic and Chronic Migraine

    • July 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Biohaven to test Rimegepant as a preventive Migraine treatment as well

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Galcanezumab reduces migraine days in patients failing on Botox

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Phase 1 study of TRV250, for acute migraine, successfully completed by Trevena

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more